Endocrine Abstracts

Diabetic Ketoacidosis (DKA) in patients with Type 2 Diabetes Mellitus (T2DM) is relatively rare and usually associated with intercurrent illness but can cause significant morbidity and mortality. SGLT2 inhibitor (SGLT2i) use has been implicated as a potential risk factor for developing euglycaemic DKA, particularly in sepsis, surgery and starvation. We aimed to investigate the common causes of DKA in T2DM in NHS Lothian to identify whether SGLT2i use was having a significant i...